AcquisitionOther
Neoleukin Therapeutics, Inc. acquired target
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Neoleukin Therapeutics, Inc. -> target · $95 million
The combined company will focus on advancing Neurogenes pipeline of differentiated genetic medicines, including NGN-401, a clinical-stage product for Rett syndrome, which uses novel gene regulation technology for a potential best-in-class profile.
Open source record (SEC) ↗